Furthermore, epidermal growth factor receptor (EGFR) mutations occur in 44%–63% of NSCLC patients and are established driver oncogenes for NSCLC that can increase the risk of BM [7,8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.